Disparities in Access to Valganciclovir Cytomegalovirus Prophylaxis in High‐Risk African American Kidney Transplant Patients
Transplant Infectious Disease · 2025
DOI: 10.1111/tid.14416 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Shipra R Bethi und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Black or African American, Cytomegalovirus Infections, Ganciclovir. Die Arbeit nennt 33 Literaturangaben. Gefördert von: Merck Pharmaceuticals.
Abstract (Originalsprache)
Background
While access and outcomes disparities for African American (AA) kidney transplant recipients are documented, there are limited studies assessing medication access disparities in transplantation. Cytomegalovirus (CMV) causes severe complications for transplant recipients, and we aimed to understand differences in access to CMV prophylaxis valganciclovir and its impact on CMV infection rates in AA transplant recipients.
Methods
This single‐center, retrospective longitudinal cohort study examined high‐risk (CMV serostatus D+/R−) adult kidney transplant recipients between June 1, 2010, and May 31, 202, through EMR abstraction. Standard univariate comparative statistics were employed alongside binary logistic regression for multivariable modeling.
Results
During the 10 year period, 418 kidney transplant recipients were included, with 179 (42.8%) identified as AA and 239 as non‐AA. There were significant differences in mean age ( p = 0.001) and private versus Medicaid insurance status ( p < 0.001). AAs experienced higher death‐censored graft loss rates (10.6% AA vs. 5.0% non‐AA, p = 0.031). CMV infection rate, opportunistic infection rate, leukopenia incidence, and death did not differ significantly between AA and non‐AA patients. AA patients were 42% less likely to receive valganciclovir out‐of‐pocket cost assistance compared to non‐AA patients (OR 0.58, [0.379–0.892], p = 0.013). When incorporating age, Medicaid status, and donor marginality in a multivariable model, the impact of AA race on utilizing assistance programs became statistically non‐significant (OR 0.70, [0.448–1.094], p = 0.118).
Conclusions
AAs were significantly less likely to leverage assistance programs or utilize personal resources to access valganciclovir. This disparity was partially explained by age, insurance status, and donor type. Despite this, CMV infection rates were similar between AA and non‐AA cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
- Department of Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
- Department of General Surgery, Jordan University of Science and Technology, Irbid, Jordan.
- Division of Infectious Disease, Medical University of South Carolina, Charleston, South Carolina, USA.
ORCID-Profile: David J Taber, Isabel Calimlim, Courtney E Harris
Förderung
- Merck Pharmaceuticals
Zitieren
APA
Bethi, S. R., Taber, D. J., Andrade, E., Mesmar, Z. M., Calimlim, I., & Harris, C. E. (2025). Disparities in Access to Valganciclovir Cytomegalovirus Prophylaxis in High‐Risk African American Kidney Transplant Patients. Transplant Infectious Disease. https://doi.org/10.1111/tid.14416
Vancouver
Bethi SR, Taber DJ, Andrade E, Mesmar ZM, Calimlim I, Harris CE. Disparities in Access to Valganciclovir Cytomegalovirus Prophylaxis in High‐Risk African American Kidney Transplant Patients. Transplant Infectious Disease. 2025. doi:10.1111/tid.14416
BibTeX
@article{Bethi2025,
author = {Bethi, Shipra R and Taber, David J and Andrade, Erika and Mesmar, Zaid M and Calimlim, Isabel and Harris, Courtney E},
title = {Disparities in Access to Valganciclovir Cytomegalovirus Prophylaxis in High‐Risk African American Kidney Transplant Patients},
journal = {Transplant Infectious Disease},
year = {2025},
doi = {10.1111/tid.14416}
}
EUVIMED